SERES THERAPEUTICS, INC. (NASDAQ:MCRB) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition. |
On March16, 2017, Seres Therapeutics, Inc. (the Company)
announced its financial results for the year and quarter ended
December31, 2016. The full text of the press release issued in
connection with the announcement is furnished as Exhibit 99.1 to
this Current Report on Form 8-K.
The information in this Item2.02 of this Form 8-K (including
Exhibit 99.1) shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly provided by specific reference in such a
filing.
| Item7.01. | Regulation FD Disclosure |
On March 16, 2017, the Company provided an updated corporate
slide presentation in the Investors Media portion of the Companys
website at www.serestherapeutics.com. A copy of the slide
presentation is attached as Exhibit 99.2 to this Current Report
on Form 8-K. The slide presentation will be archived for
approximately 30 days on the Companys website.
The information in Item 7.01 of this Current Report on Form 8-K
(including Exhibit 99.2) shall not be deemed filed for purposes
of Section 18 of the Exchange Act, or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing. The Company undertakes no
obligation to update, supplement or amend the materials attached
hereto as Exhibit 99.2.
| Item9.01. | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibit relating to Item2.02 shall be deemed to be
furnished, and not filed:
|
Exhibit No. |
Description |
|
| 99.1 | Press Release issued on March16, 2017 | |
| 99.2 | Corporate Deck as of March 16, 2017 |
About SERES THERAPEUTICS, INC. (NASDAQ:MCRB)
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Company is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; obesity and metabolic syndrome; other inflammatory diseases; cancer chemotherapy and immune suppression, and rare genetic diseases. SERES THERAPEUTICS, INC. (NASDAQ:MCRB) Recent Trading Information
SERES THERAPEUTICS, INC. (NASDAQ:MCRB) closed its last trading session up +0.14 at 9.27 with 91,139 shares trading hands.
